Microprolactinoma: Medical or surgical treatment as first line approach? The case for medical therapy

Journal of Endocrinological Investigation

Volumn 23, Issue 2, 2000, Pages 122-124

  Rees, D A ^a   Davies, J S ^a   Scanlon, M F ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GESTAGEN; NERVE GROWTH FACTOR; PERGOLIDE; PROLACTIN; PROTIRELIN; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE; THYROTROPIN;

DIAGNOSTIC ACCURACY; DRUG COST; DRUG SAFETY; HUMAN; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; NAUSEA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PITUITARY GLAND EXAMINATION; PROLACTINOMA; VOMITING;

EID: 0034072061     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343691     Document Type: Note

References (14)

1. Davis M.J., Howlett T.A. A survey of the current methods used in the UK to assess pituitary function. J. Royal Soc. Med. 1996, 98: 159-164.
2. Scanlon M.F., Peters J.R., Salvador J., Richards S.H., John R., Howell S., Williams E.D., Thomas J.P., Hall R. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinemia due to prolactinomas and non-functional pituitary tumors: relationship to adenoma size at surgery. Clin. Endocrinol. (Oxf.) 1986, 24: 435-446.
3. Sawers H.A., Robb O.J., Walmsley D., Strachan F.M., Shaw J., Bevan J.S. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinemia. Clin. Endocrinol. (Oxf.) 1997, 46: 321-326.
4. Greenspan S.L, Neer R.M., Ridgway E.C., Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 1986, 104: 777-782.
5. Testa G., Vegetti W., Motta T., Alagna F., Bianchedi D., Carlucci C., Bianchi M., Parazzini F., Crosignani P.G. Two-year treatment with oral contraceptives in hyperprolactinemic patients contraception. Contraception 1998, 58: 69-73.
6. Fahy U.M., Foster P.A., Torode H.W., Hartog M., Hull M.G. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. J. Gynecol. Endocrinol. 1992, 6: 183-188.
7. Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. J. Fertil. Steril. 1993, 59: 671-673.
8. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. J. Endocr. Rev. 1992, 13: 220-240.
9. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F., for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Engl. J. Med. 1994, 331: 904-909.
10. Colao A., Di Sarno A., Sarnacchiaro F., Ferone D., Di Renzo G., Merola B., Annunziato L., Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Clin. Endocrinol. Metab. 1997, 82: 876-883.
11. Duranteau L., Chanson P., Lavionne A., Horlait S., Lubetski J., Kuhn J.M. Effects of new dopaminergic agonist CV 205-502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas. Clin. Endocrinol. (Oxf.) 1991, 34: 25-29.
12. Wang C., Lam K.S.L., Ma J.T.C., Chan T., Liu M.Y., Yeung R.T.T. Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin. Endocrinol. (Oxf.) 1987, 27: 363-371.
13. Tyrrell J.B., Lamborn K.R., Hannegan LT., Applebury C.B., Wilson C.B. Transsphenoidal microsurgical therapy of prolactinomas: initial outcome and long-term results. Neurosurgery 1999, 44: 254-261.
14. Molitch M.E. Prolactinoma. In: Melmed S. (Ed.), The Pituitary. Blackwell Scientific, Boston, 1995, p. 443.